Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mild Cognitive Impairment: early-phase trial registry
100 of 206 indexed Mild Cognitive Impairment trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #45 of 28,707 conditions by registered trial count.
206 US clinical trials · 100 currently recruiting · #45 of 28,707 conditions by registered trial count
Mild Cognitive Impairment: 206 US clinical trials tracked, 100 recruiting.
Mild Cognitive Impairment is the subject of 206 registered US clinical trials on ClinicalTrials.gov, 100 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 9 of these trials.
Enrollment posture brief
Registry condition mild-cognitive-impairment
OPEN 100 | RECR 49% | LATE 8 | EARLY 52 | RANK #45 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Chronic Graft Versus Host Disease (48% recruiting · 31 trials)
Mild Cognitive Impairment lists 100 open slots (49% of 206 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mild Cognitive Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mild Cognitive Impairment is recruiting above its size-band peers.
100 of 206 indexed trials (48.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Mild Cognitive Impairment trials is spread across many organizations.
Massachusetts General Hospital accounts for 9 of 206 trials (4.4%). 114 distinct sponsors appear on at least one study for this condition label.
-
Typical Mild Cognitive Impairment enrolment sits around 81 participants.
Median target enrolment is 81 among the 206 trials that report a genuine target (sentinel values excluded). 114 of those (55.3%) plan for fewer than 100 participants.
-
Mild Cognitive Impairment research is mostly interventional.
168 interventional and 38 observational studies make up this index (81.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
206 total, page 3 of 5
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
Eli Lilly and Company
NCT02951598
ACHIEVE Brain Health Follow-Up Study
Johns Hopkins University
NCT05532657
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
C2N Diagnostics
NCT06025877
MCI: CPAP Treatment of OSA (Memories2)
University of Pennsylvania
NCT03113461
Metformin in Alzheimer's Dementia Prevention
Columbia University
NCT04098666
Tai Ji Quan and Cognitive Function in Older Adults With Mild Cognitive Impairment
Oregon Research Institute
NCT04070703
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
Northwestern University
NCT03960476
Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain
Massachusetts General Hospital
NCT05373745
Music Improvisation Training on Cognitive Function in Older Adults
University of California, San Francisco
NCT06721390
A Physical Activity Intervention to Promote Cognitive Health, Cardiovascular Health and Sleep in Older Latinos
University of Pennsylvania
NCT05030948
Supportive Care for Cognitively Impaired Patients and Families
Stanford University
NCT03881579
Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
NYU Langone Health
NCT04784416
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Weill Medical College of Cornell University
NCT03649724
A Novel Computer-Based Functional Skills Assessment and Training Program
i-Function
NCT04679441
Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure
Indiana University
NCT05601817
Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI
University of Pennsylvania
NCT04251130
Water-based Activity to Enhance Recall in Veterans
VA Office of Research and Development
NCT04296565
Everyday Memory Impairment in PD-related Cognitive Decline
Washington University School of Medicine
NCT04474379
Neurofeedback to Improve Working Memory in Mild Cognitive Impairment
University of California, San Diego
NCT04566900
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
University of Michigan
NCT05584241
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Aptinyx
NCT04148391
The Brain Health Champion Study
Brigham and Women's Hospital
NCT03772977
Remote Game-based Exercise Program for Cognitive and Motor Function Improvement
University of California, Los Angeles
NCT05235113
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Gregory Jicha, MD, PhD
NCT04120766
A Scalable Nutrition Adherence Intervention
Florida State University
NCT06121986
Glutathione in Mild Cognitive Impairment
Baylor College of Medicine
NCT03493178
Multi-Center Study of Sensory Stimulation to Improve Brain Function
Cognito Therapeutics
NCT03556280
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Boston University
NCT03560960
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Washington University School of Medicine
NCT04685590
PRogram to Improve Stress-levels and Enhance Memory
Emory University
NCT05845918
rTMS in Older Adults With MCI and AUD
Medical University of South Carolina
NCT05896332
ALSENLITE: Senolytics for Alzheimer's Disease
Mayo Clinic
NCT04785300
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Ali Rezai
NCT05469009
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai
NCT06069843
Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment
NYU Langone Health
NCT05601583
Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study
American College of Radiology
NCT02420756
Genetic Studies in Familial Dementia
University of Miami
NCT04680013
An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00297414
Cognitive Assessment of Elderly Primary Care Patients
University of Pittsburgh
NCT01492335
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
C2N Diagnostics
NCT05477056
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
GE Healthcare
NCT01028053
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
Alzheimer's Disease Cooperative Study (ADCS)
NCT01078636
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
University of California, Berkeley
NCT04206670
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
Pamlab
NCT01370954
Cognitive and Aerobic Resilience for the Brain
Indiana University
NCT02390453
Internet-based Conversational Engagement Clinical Trial
Massachusetts General Hospital
NCT02871921
Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects
University of Utah
NCT03466736
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
AgeneBio
NCT03486938
A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment
Janssen Research & Development
NCT02419183
Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial
Thomas Jefferson University
NCT04259047
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 28 |
| Phase 3 | 3 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Mild Cognitive Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mild Cognitive Impairment trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mild Cognitive Impairment page
206 registered trials, 100 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 100 Mild Cognitive Impairment trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Mild Cognitive Impairment trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mild Cognitive Impairment condition card totals 206 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.